| ASCLF Stock | | | USD 0.18 0.00 0.00% |
Insider
Jinzi Wu is Chairman Founder of Ascletis Pharma
| Age | 60 |
| Phone | 86 571 8538 9730 |
| Web | https://www.ascletis.com |
Ascletis Pharma Management Efficiency
The company has return on total asset
(ROA) of
(0.053) % which means that it has lost $0.053 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.0632) %, meaning that it generated substantial loss on money invested by shareholders. Ascletis Pharma's management efficiency ratios could be used to measure how well Ascletis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Ascletis Pharma has accumulated 2.75
M in total debt with debt to equity ratio
(D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Ascletis Pharma has a current ratio of 28.35, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Ascletis Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Ascletis Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ascletis Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ascletis to invest in growth at high rates of return. When we think about Ascletis Pharma's use of debt, we should always consider it together with cash and equity.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people. Ascletis Pharma [ASCLF] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Ascletis Pharma Leadership Team
Elected by the shareholders, the Ascletis Pharma's board of directors comprises two types of representatives: Ascletis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascletis. The board's role is to monitor Ascletis Pharma's management team and ensure that shareholders' interests are well served. Ascletis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascletis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ascletis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ascletis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.